In clinical trials the treatment — which involves extracting individual patients» immune T - cells, modifying them to seek out tell - tale biological markers associated with blood cancers
like aggressive lymphoma, and then pumping those modified killer cells back into the body — has shown major promise, in some cases eliminating all signs of the cancer in patients six months after treatment.
Not exact matches
Management strategies for patients with mantle cell
lymphoma continue to demonstrate pendulum -
like swings between those appropriate for low - grade
lymphoma, and those appropriate for very
aggressive lymphoma.
More
aggressive forms of
lymphoma like large cell
lymphoma may only survive months despite multi-agent chemotherapy.